Imunon Inc

Research Imunon Inc (IMNN) on Bullrun: market cap USD 7.06M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMNN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 7.06M
• Financial periodFY2025
• Net incomeUSD 14.50M
• Free cash flow-USD 14.18M

Valuation Snapshot

latest market cap is USD 7.06M.

About Imunon Inc

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.

Frequently asked questions

What is Imunon Inc's market cap?

Imunon Inc's market capitalization is USD 7.06M.

What does Imunon Inc do?

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.